0001676135-18-000003.txt : 20180301 0001676135-18-000003.hdr.sgml : 20180301 20180301145421 ACCESSION NUMBER: 0001676135-18-000003 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20180301 DATE AS OF CHANGE: 20180301 EFFECTIVENESS DATE: 20180301 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Quentis Therapeutics, Inc. CENTRAL INDEX KEY: 0001676135 IRS NUMBER: 475146433 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-306751 FILM NUMBER: 18656473 BUSINESS ADDRESS: STREET 1: 430 E 29TH STREET STREET 2: SUITE 1005 CITY: NEW YORK STATE: NY ZIP: 10016 BUSINESS PHONE: 646-440-9248 MAIL ADDRESS: STREET 1: 430 E 29TH STREET STREET 2: SUITE 1005 CITY: NEW YORK STATE: NY ZIP: 10016 FORMER COMPANY: FORMER CONFORMED NAME: Quentis, Inc. DATE OF NAME CHANGE: 20160601 D 1 primary_doc.xml X0708 D LIVE 0001676135 Quentis Therapeutics, Inc. 430 E 29th Street Suite 1005 NEW YORK NY NEW YORK 10016 (646) 440-9248 DELAWARE Quentis, Inc. Corporation true 2015 Michael Aberman 430 E 29th Street Suite 1005 New York NY NEW YORK 10016 Executive Officer Director Amy Schulman 430 E 29th Street Suite 1005 New York NY NEW YORK 10016 Director Carlo Rizzuto 430 E 29th Street Suite 1005 New York NY NEW YORK 10016 Executive Officer Director Michael Foley 430 E 29th Street Suite 1005 New York NY NEW YORK 10016 Director Biotechnology Decline to Disclose 06b false 2018-02-15 false true false 0 47874995 19674997 28199998 false 16 0 0 0 false Quentis Therapeutics, Inc. /s/Michael Aberman Michael Aberman Chief Executive Officer 2018-03-01